Wellbeing Digital Sciences Inc. - KONEF STOCK NEWS

Wellbeing Digital Sciences Inc. (OTC: KONEF) has announced CEO Najla Guthrie's participation in the Wonderland Miami Conference from November 3-5, 2022. This major event in psychedelic medicine will cover critical topics, including drug policy and innovative therapies. Guthrie will be on three panels discussing the politics of psychedelic medicine, building centers of excellence, and the application of ketamine in pain and depression treatments. The conference aims to bring together industry leaders and innovators to advance mental health solutions.

Wellbeing Digital Sciences Inc. (OTC: KONEF) announced the participation of Erin Lewis, Scientific Director of KGK Sciences, at the Supply Side West Conference from October 31 to November 4, 2022, in Las Vegas, NV. Lewis will be on the panel titled “Exploring the Microbiome: Science, Innovation and Delivery” on November 1 at 1 PM. The session will address health benefits of the microbiome, market data insights, and technological innovations related to microbial health impacts. For more details, visit wellbeingdigital.co.

Wellbeing Digital Sciences Inc. (OTC: KONEF) commends Alberta's new regulations aimed at governing psychedelic drug administration as adjunct therapy in licensed facilities. These regulations, set to take effect in January 2023, mandate clinics to secure licenses and ensure qualified staff involvement. CEO Najla Guthrie views this as a progressive move towards legitimizing psychedelic therapies, emphasizing the need for expanded access amid existing federal restrictions. Despite challenges, the regulations signal growing acceptance within the medical community regarding psychedelic treatments.

Wellbeing Digital Sciences Inc. (OTC: KONEF) has completed the CMC package for a Phase 2A clinical trial evaluating its 1.5 mg psilocybin capsules aimed at treating fragile X syndrome, a leading cause of autism spectrum disorder (ASD). The submission to Health Canada will include detailed manufacturing processes and batch records. This trial is being conducted in partnership with Nova Mentis Life Science Corp., which aims to explore psilocybin's therapeutic use across various conditions, including PTSD and diabetes.

Wellbeing Digital Sciences Inc. (OTC: KONEF) has signed a Letter of Intent to manage three additional clinics in San Diego and Las Vegas. This expansion is part of the company’s strategy to increase its North American clinical footprint and enhance treatment options through innovative therapies, including IV Ketamine and psychedelic medicine. The transaction is expected to complete in Q4, pending approvals and due diligence. Wellbeing aims to replicate previous growth successes to maximize shareholder value.

Wellbeing Digital Sciences Inc. has launched a new Clinical Research Center in London, Ontario, aiming to enhance research in nutraceuticals, cannabinoids, hemp, and psychedelics. The facility will support clients in clinical trials and regulatory processes, reflecting over 25 years of expertise. A grand opening ceremony is scheduled for September 29, 2022. With over 400 clinical trials completed and 150 publications, KGK Sciences Inc. continues to lead advancements in the sector, fostering innovation in mental healthcare solutions.

Wellbeing Digital Sciences Inc. (OTC: KONEF, NEO: MEDI) announces CEO 's participation in Microdose’s Psychedelic Capital conference on September 29, 2022, at 1:30 p.m. ET. Guthrie will feature on the panel discussing Psychedelic Patents: Navigating the Controversial IP Landscape. The company focuses on evidence-based mental healthcare, including psychedelic medicine and digital therapeutics.

For more details or to schedule a meeting with Wellbeing’s management, contact Natalie Dolphin at ndolphin@wellbeingdigital.co.

Wellbeing Digital Sciences Inc. (OTC: KONEF) reported $1.16 million in revenue for the quarter ending July 31, 2022, reflecting a 2.5% increase year-over-year. The net loss significantly declined to $4.06 million from $27 million in the prior year, primarily due to a large provision for acquisition-related costs. However, total assets decreased by 21.5% to $17.22 million. The company aims to lead in ketamine-enhanced treatments in North America and has acquired 15 clinics, with plans for infrastructure expansion.

Wellbeing Digital Sciences announced the appointment of Najla Guthrie as a member of the Benzinga Psychedelic Advisory Council. This council features key leaders in the emerging sector of psychedelic medicine, aimed at sharing insights on industry developments. Guthrie expressed her honor in joining esteemed colleagues and emphasized the growth of investor interest in the psychedelic space. The Benzinga Psychedelics Capital Conference is set to further facilitate networking among industry leaders. Wellbeing Digital Sciences continues to focus on innovative clinical solutions in mental healthcare.